Next Article in Journal
A Comparative Analysis of Sparisoma cretense in Island Environments: Unraveling Metal Accumulation Differences in the Canary Islands (Spain, NW African Waters)
Previous Article in Journal
Evaluation of the Composition of the Cholesterol, Tocopherols, β-Carotene and Fatty Acids Profile of the Liver Tissue of Male Water Buffaloes (Bubalus bubalis) Managed in Different Ecosystems of the Eastern Amazon
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Animals
Volume 13
Issue 24
10.3390/ani13243786
animals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

In Vitro Antimicrobial Properties and Their Mechanisms in Relation to Reactive Oxygen Species of Canine Platelet-Rich Fibrin

by
Ravisa Warin
1,
Preeyanat Vongchan
2,
Witaya Suriyasathaporn
1,3,4,
David C. Hall
5,
Ratchadaporn Boripun
6 and
Wanna Suriyasathaporn
1,3,*
1
Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand
2
Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
3
Research Center of Producing and Development of Products and Innovations for Animal Health and Production, Chiang Mai University, Chiang Mai 50100, Thailand
4
Asian Satellite Campuses Institute, Cambodian Campus, Nagoya University, Nagoya 464-8601, Japan
5
Faculty of Veterinary Medicine, University of Calgary, Calgary, AB T2N 4Z1, Canada
6
Akkhraratchakumari Veterinary College, Walailak University, Nakhon Si Thammarat 80160, Thailand
*
Author to whom correspondence should be addressed.
Animals 2023, 13(24), 3786; https://doi.org/10.3390/ani13243786
Submission received: 30 October 2023 / Revised: 24 November 2023 / Accepted: 6 December 2023 / Published: 8 December 2023
(This article belongs to the Section Companion Animals)
Browse Figures
Versions Notes

Abstract

:

Simple Summary

Bacterial infections can often lead to complications in wound healing. The overuse of antimicrobial drugs can cause antimicrobial resistance, making it necessary to find alternative therapeutic options for wound care. Platelet-rich fibrin (PRF) has been used for tissue regeneration, but until now, its application for antimicrobial activity has been limited to periodontal pathogens. In this study, we aimed to determine the antimicrobial effects of canine PRF (cPRF) against bacteria from the clinical wound of a dog and to investigate the mechanism of its antibacterial activity, which involves the formation of reactive oxygen species (ROS). Our results showed that cPRF had a significant antimicrobial effect against Escherichia coli between 4 and 24 h, resulting from the release of ROS. Based on these findings, cPRF, a rich source of growth factors that accelerate the wound healing process, could be used as a biological material for wound infection treatment, benefiting veterinary medicine.

Abstract

Platelet-rich fibrin (PRF), which has been shown to promote wound and bone regeneration, has demonstrated antimicrobial properties against periodontal pathogens. However, in veterinary medicine, no study has determined the antimicrobial effects of canine platelet-rich fibrin (cPRF). Therefore, this study aimed to determine the antimicrobial effect of cPRF against E. coli and S. pseudintermedius found in dogs’ wounds and against the standard strain S. aureus. Additionally, the mechanism of the existing antibacterial activity of cPRF, which involves the formation of reactive oxygen species (ROS), was tested. Blood samples from six dogs were processed for cPRF. The antimicrobial properties of three groups (growth control, cPRF, and drug control) were evaluated at 0.5, 4, 8, and 24 h using a time–kill assay. The killing mechanisms involving ROS were evaluated using horseradish peroxidase (HRP) to suppress ROS production in PRF (PRF-SR). Subsequently, tests for antimicrobial properties and ROS generation were compared to those of the growth control and cPRF groups. The results showed that cPRF had significant antimicrobial properties against E. coli but no antimicrobial properties against S. pseudintermedius. After the ROS suppression, PRF-SR did not show an antimicrobial property against E. coli. Moreover, cPRF-treated bacteria exhibited significantly greater intracellular ROS than PRF-SR. In conclusion, canine PRF showed an antimicrobial effect against E. coli, and its antibacterial mechanism was related to releasing ROS.

1. Introduction

Skin injuries are common in small animal practice, and wounds classified as Class II to Class IV [1] can lead to complications in wound healing due to bacterial contamination. While the current standard treatment for wounds in veterinary medicine is the use of broad-spectrum antibiotics, the overuse of antibiotics has led to the emergence and rapid spread of antibiotic-resistant bacteria [2,3]. This poses a significant challenge for health practitioners and a massive threat to human and animal health. Research has found that limiting the use of antibiotics for six months on a dairy farm results in a reduction in antibiotic-resistant bacteria [4]. Therefore, it is crucial to introduce alternative treatments for less severe bacterial infections, especially Class II and Class III wounds, in order to minimize the unnecessary use of antibiotics. Doing so will help to mitigate the emergence of antibiotic-resistant bacteria and preserve the effectiveness of antibiotics for future use.
Blood clots are crucial in the natural healing of wounds. They combine platelets and red blood cells, forming a semi-flexible fibrin fiber network [5]. Platelets are believed to be an effective treatment for wound care and play a crucial role in the body’s defense against infection [6]. The natural products of platelets, such as platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), have been utilized in human and veterinary medicine [7,8]. PRF is ideal for tissue regeneration and growth stimulation as it has slower and prolonged releases of growth factors compared to PRP [9], in which PRP requires an anticoagulant, causing delayed wound healing [10]. Additionally, preparing PRP can be complicated and expensive [11]. Therefore, the use of PRF may be more encouraged than PRP. Furthermore, PRP and PRF have demonstrated antimicrobial effects against Porphyromonas gingivalis in dentistry [12,13]. In veterinary medicine, PRP has been found to inhibit Escherichia coli growth [14], but no study has evaluated the antimicrobial effects of PRF.
Research has indicated that platelets can generate reactive oxygen species (ROS) that aid in combating microbial infections [15,16]. For example, porcine platelets activated by bacterial lipopolysaccharide (LPS) generate superoxide anions that might be capable of fighting against bacterial infections [17]. However, it was discovered that the ROS generated by equine platelets did not significantly contribute to bacterial eradication [18], and this discrepancy might be due to species differences or different stimuli. E. coli is a pathogen that causes various infections in canines, including wound infections [19], and is the most frequently isolated bacterium in surgical wound infections [20]. In contrast, Staphylococcus pseudintermedius is the most common bacterium in canine wounds [21,22]. Recent research has reported on the wound-healing property of canine platelet-rich fibrin (cPRF) in vitro and found that cPRF increased fibroblast cell proliferation and induced a significantly faster wound closure than the control [23]. However, no study has yet determined whether cPRF can effectively combat E. coli and S. pseudointermedius or how it does so. This study explored the in vitro antimicrobial efficacy of canine PRF against bacteria. Time–kill assays were utilized to assess the antimicrobial effect of canine PRF. The study also aimed to determine the mechanism through which canine PRF combats bacteria, subsequently evaluating its existing antibacterial properties by measuring ROS production and examining its antibacterial impact after ROS suppression.

2. Materials and Methods

2.1. Ethical Approval, Animal Selection, and Study Design

The animal care and use committee of the Faculty of Veterinary Medicine at Chiang Mai University, Thailand (FVM-CMU-ICUC Ref. No. S27/2563) approved the use of animals for the experiment. The laboratory animal ethics laws and protocols were followed to minimize animal suffering and the number of animals used. The dog owners were informed and consented before their dogs participated in the experiment.
The study involved six healthy Labrador retriever dogs (three males and three females) from Border Patrol Police Division 33, Chiang Mai, Thailand. As previously reported, the dogs were evaluated for their health status and management [23]. The experiment involved collecting and processing 10 mL of blood from each dog to prepare the canine PRF (cPRF), as described in [23]. The experiment compared the antimicrobial effects of three conditions: (1) growth control using phosphate buffer saline (PBS) (Gibco, Life Technologies Corporation, New York, NY, USA); (2) cPRF; and (3) drug control using antibiotics. The time–kill assay was used at 0.5, 4, 8, and 24 h. To determine the antibacterial mechanism related to the ROS of cPRF, both antimicrobial efficacy and its ROS generation after ROS suppression via horseradish peroxidase (HRP) were tested using a time–kill assay and the fluorescent probe 2,7-dichlorodihydrofluorescein diacetate (H2DCFDA), respectively, for the specified bacteria killed by cPRF (Figure 1).

2.2. Bacterial Preparation

Bacterial strains used in this study were S. aureus (ATCC 29213) (SAs), E. coli ATCC 25922 (ECs), clinical isolates of S. pseudintermedius (SPc), and E. coli (ECc). The two clinical isolates were obtained from cases of canine surgical wound infection submitted to the Chiang Mai University Veterinary Teaching Hospital for routine microbial culture and susceptibility testing, which were identified using automated identification systems (VITEK® 2 COMPACT, bioMerieux, Marcy l’Etoile, France). Subsequently, these isolates confirmed the identification using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI Biotyper, Bruker Daltonik GmbH, Bremen, Germany). For antimicrobial susceptibility testing, the minimal inhibitory concentration (MIC) values were used and categorized into S, I, or R according to susceptible, intermediate, or resistant. All isolates were defrosted and cultured in Brain Heart Infusion (BHI) agar (Himedia®, Mumbai, India) at 37 °C overnight before use.

2.3. Time–Kill Assay

Time–kill assays were conducted with modifications according to Clinical Laboratory Standards Institute (CLSI) guidelines [24,25]. The bacterial suspension was adjusted to a final 5 × 105 CFU/mL concentration. The bacterial suspensions were prepared in a 96-well plate for 200 µL/well volume in a 1:1 ratio. Antibiotics, including Enrofloxacin (Genfloxcin; General Drugs House Co., Ltd., Pathum Thani, Thailand) 0.5 µg/mL, Clindamycin (MACCLINDA; Macrophar Co., Ltd., Bangkok, Thailand) 0.5 µg/mL, Gentamicin (Gentamicin sulfate; T.P. Drug Laboratories Co., Ltd., Bangkok, Thailand) 4 µg/mL, and Clindamycin 0.5 µg/mL, were used as the drug controls for ECc, SPc, ECs, and SAs, respectively, according to CLSI guidelines [24,26]. The incubation was carried out at 37 °C. The assay was performed in duplicate and repeated twice. The bacterial colony numbers were quantified after incubation at 0.5, 4, 8, and 24 h. At the specified time, aliquots of the bacterial suspension were diluted using serial 10-fold dilutions in PBS. Then, a 50 µL sample of each dilution was plated onto Muller–Hinton Agar (MHA) (Himedia®, Maharashtra, India). After overnight incubation, the number of viable bacteria was determined by counting the colonies. The number of colonies ranging from 30 to 300 was considered countable.

2.4. Antimicrobial Mechanism RELATED to ROS Determination

The antimicrobial mechanism related to ROS determination was tested for the specified bacteria killed by cPRF according to the time–kill assay result using an enzymatic treatment to suppress superoxide as a ROS. The horseradish peroxidase (HRP) enzyme (Sigma Aldrich, St. Louis, MO, USA), the enzyme for suppressing the peroxide released from the cPRF, at a final concentration of 0.2 mg/mL, was mixed with cPRF exudate at a ratio of 1:1. The solution was sterilized with a sterile syringe filter (Corning®, Corning Incorporated, Berlin, Germany) and incubated at 37 °C for 30 min before use as cPRF with suppressed ROS (PRF-SR). The bacterial suspension was treated with PBS as a control, cPRF, and PRF-SR for a total volume of 200 µL/well (ratio 1:1). Numbers of colonies were quantified under a similar condition using time–kill assays as previously described.
The ROS generations of a control condition using PBS, cPRF, and PRF-SR at 0.5, 4, 8, and 24 h were measured using a fluorescent probe 2,7-dichlorodihydrofluorescein diacetate (H2DCFDA) (Invitrogen, Thermo Fisher Scientific, Life Technologies Corporation, Eugene, OR, USA) according to the manufacturer’s instructions and Jyung and colleagues [27], with slight modifications. Briefly, at the desired time points, bacteria were incubated with H2DCFDA dye at a final concentration of 10 µM at 37 °C for 30 min. Subsequently, the fluorescent intensity was detected using a fluorescence spectrophotometer (Synergy™ H1, BioTek® Instruments Incorporated, Winooski, VT, USA) at excitation/emission wavelengths of 493/520 nm. The experiment was performed in triplicate. Fluorescent intensity (Relative Fluorescence Units: RFU) was presented as an F/F0 value, calculated via the fluorescence of the test (F) divided by the fluorescence of the control at 0.5 h (F0).

2.5. Statistical Analysis

The data are presented as means and standard errors (SEs). Non-normally distributed data were transformed using a logarithm. As the data were collected from the same dogs, repeated measure analyses were performed using a generalized linear mixed model (Proc mixed, SAS, 2004) to identify group differences. All independent variables, including groups and times, were treated as categorical variables. The number of colonies and F/F0 values were dependent variables separately analyzed among groups at 0.5, 4, 8, and 24 h. Least-square means were calculated for all comparisons, and significance was defined at p < 0.05.

3. Results

Table 1 presents the results of the antimicrobial susceptibility tests carried out on all the isolates. For SPc isolates that exhibited phenotypic resistance to Oxacillin with a MIC greater than 0.5 µg/mL, Methicillin-resistant S. pseudintermedius (MR-SPc) was considered. Both SPc isolates were also resistant to benzylpenicillin, clindamycin, enrofloxacin, marbofloxacin, and trimethoprim/sulfamethoxacin. In contrast, SAs, ECs, and ECc isolates displayed sensitivity to almost all the antibiotics tested.
Representative time-lapse images of bacterial colonies in the time–kill assays, at 0.5 and 24 h after culturing among different groups, are shown in Figure 2A–D. The results demonstrate that cPRF exhibits a lower bacterial colony count than the growth control, indicating the presence of antimicrobial activity of cPRF in ECs and ECc cultures (Figure 2A,B). The antimicrobial effects of cPRF on all bacteria compared to the control and antibiotics at 0.5, 4, 8, and 24 h are displayed in Figure 2E–H. At 0.5 h, there was no discernible difference in the number of E. coli colonies between the growth control and cPRF. However, cPRF had significantly fewer colonies in both E. coli strains at 4, 8, and 24 h than the growth control (Figure 2E,F). In comparison, within cPRF, the numbers of bacteria at 4 and 8 h were significantly lower than at 0.5 h for ECs (p < 0.0001) and ECc (p = 0.03), respectively. There was no antimicrobial effect of cPRF on MR-SPc and SAs (Figure 2G,H). The colonies in the antibiotic group were lower than the control and cPRF at 4, 8, and 24 h for MR-SPc and 8 and 24 h for SAs.
Figure 3 compares the number of colonies of E. coli among the growth control, PRF-SR, and cPRF. No difference in bacterial growth was observed among groups at 0.5 h. cPRF showed a significant decrease in the number of colonies at 4, 8, and 24 h of incubation compared with the growth control and PRF-SR. In comparison, within cPRF, the number of bacteria decreased significantly at 4 h compared to 0.5 h.
In Figure 4, the ROS generation of cultures stimulated with ECs was compared among different groups based on their cell fluorescence intensity. At 0.5 h, the fluorescence intensity was similar in all groups. However, at 4, 8, and 24 h, cPRF had a significantly higher fluorescence intensity than the growth control and PRF-SR. There were no significant differences in the fluorescent intensity between the growth control and PRF-SR at any time.

4. Discussion

PRF, the new generation of platelet concentrates, has been shown to promote soft tissue wound healing and bone regeneration in both human and veterinary medicine [28,29,30] due to its growth factors that stimulate healing by promoting granulation tissue formation and angiogenesis [31]. Moreover, in dentistry, PRF has been demonstrated to promote bone regeneration in rabbit teeth [32,33]. While previous studies have explored the antimicrobial effects of PRF on periodontal pathogens [12,13,34,35], in veterinary medicine, this study is the first to investigate the antimicrobial effects of PRF produced from canine blood samples against both standard bacteria and bacteria from the clinical wound of a dog. These findings are important, as wound infections are a serious concern. For the identification of SPc isolates, molecular methods are accurate in differentiating S. pseudintermedius from the S. intermedius group (SIG). However, MALDI-TOF MS has become a highly reliable and rapid tool for discriminating the organisms belonging to this group [36,37]. Similar to S. aureus infection, S. pseudintermedius, primarily found in animals, is an opportunistic pathogen that causes disease in conditions with impaired skin barriers, such as surgical procedures, immunosuppressive disorders, and atopic dermatitis [37]. Regarding antimicrobial susceptibility, both MR-SPc isolates were classified as multidrug-resistant (MDR) [38], which is increasingly common in small animal veterinary practice [39,40,41,42]. This poses a challenge due to limited antibiotic use and the potential for spreading among animals [43].
In this study, cPRF showed a significant decrease in E. coli growth at 4, 8, and 24 h compared to the control group. These findings are consistent with a previous study that showed equine platelets from PRP can significantly decrease E. coli growth [18]. Interestingly, the present research discovered that cPRF might have longer antimicrobial effects against E. coli than PRP, which had no antimicrobial effects after 4 h in a previous study [18]. This suggests that concentrated leukocytes and a three-dimensional fibrin network contained in PRF can facilitate longer antimicrobial mechanisms [44,45]. Long-term antibiotic treatment can induce the mutation of E.coli into the MDR E.coli strain [46]. As a result, using cPRF as an antimicrobial agent against E.coli could reduce antibiotic use and antimicrobial resistance. At 0.5 h, there was no significant difference in E. coli growth in the culture with PRF compared to the control group. Burnouf and colleagues found that PRP had antimicrobial properties against E. coli after 3 h of incubation [47]. However, our findings showed that cPRF had no antibacterial properties against Methicillin-resistant S. pseudintermedius and S. aureus. Bayer and colleagues also found that some staphylococcal strains resisted the antimicrobial molecules of platelets [48]. The study of Wu and colleagues revealed that lipoteichoic acid (LTA), a cell wall component of Gram-positive bacteria, can inhibit platelets’ mediator release and platelet–leukocyte aggregation [49]. Thus, platelet response to infection was altered and might relate to the absent antimicrobial effect of cPRF against Gram-positive bacteria. However, a study using PRP from human samples found antimicrobial effects against S. aureus [50]. It is possible that the antimicrobial activity of platelet microbiocidal proteins, one of the antimicrobial molecules from platelets, is directly related to staphylococcal strains, in which different strains show different susceptibilities [48], and species differences between humans and animals should be noted.
Reactive oxygen species (ROS) are involved in wound-healing processes, including cell motility, cytokine signal transduction, and angiogenesis [51]. Human platelets have been shown to release superoxide and hydrogen peroxide, both of which exert antibacterial action [52,53]. However, ROS production by canine PRF has not been documented. Therefore, this study was the first to investigate the involvement of ROS in the antimicrobial properties of canine PRF. After suppressing ROS production, PRF without ROS or PRF-SR could not kill E. coli (Figure 3). This result demonstrated that the antibacterial activity of cPRF resulted from ROS. This finding was supported by a previous study that showed that the release of peroxide in PRF involved its antimicrobial properties [54]. The fluorescence intensity of ROS in cPRF was significantly greater than that of ROS-suppressed PRF and the control at 4, 8, and 24 h (Figure 4), supporting our finding that ROS production was related to the antibacterial properties of PRF (Figure 3). This finding also indicates that PRF could stimulate the production of endogenous ROS, causing the killing of bacteria, which has been proposed as a common mechanism whereby bactericidal antibiotics induce bacterial cell death [55]. The pivotal role of ROS and mitochondria in platelet function has recently emerged, regulating platelet activation, aggregation, and recruitment and tuning several cellular signaling pathways (for a review, see [56]). Nicotinamide adenine dinucleotide (phosphate) (NAD(P)H) oxidase (NOX) isoforms are the main sources of ROS in platelets, followed by cyclooxygenase (COX), xanthine oxidase (XO), and mitochondrial respiration [57].

5. Conclusions

In conclusion, canine platelet-rich fibrin exhibited promising partly antimicrobial results by lowering E. coli growth from 4 to 24 h, but not the growth of S. pseudintermedius. The present study demonstrated that the bacterial killing mechanism of canine PRF involved the production of reactive oxygen species. Based on these findings, canine PRF, a rich source of the growth factors that accelerate wound healing, can be partly recommended as a biological material for wound infection treatment. Future investigations studying the antimicrobial effects of canine PRF in vivo should be undertaken to confirm these findings.

Author Contributions

Conceptualization, R.W., P.V., W.S. (Wanna Suriyasathaporn) and W.S. (Witaya Suriyasathaporn); methodology, R.W., P.V. and R.B.; validation, R.W., W.S. (Wanna Suriyasathaporn) and P.V.; investigation, R.W., P.V. and R.B.; data curation, W.S. (Witaya Suriyasathaporn) and D.C.H.; writing—original draft preparation, R.W. and W.S. (Witaya Suriyasathaporn); writing—review and editing, R.W., P.V., W.S. (Wanna Suriyasathaporn), W.S. (Witaya Suriyasathaporn) and D.C.H.; visualization, R.W., W.S. (Wanna Suriyasathaporn) and W.S. (Witaya Suriyasathaporn); supervision, P.V., W.S. (Wanna Suriyasathaporn), W.S. (Witaya Suriyasathaporn) and D.C.H.; project administration, W.S. (Wanna Suriyasathaporn) and W.S. (Witaya Suriyasathaporn); funding acquisition, W.S. (Wanna Suriyasathaporn) and W.S. (Witaya Suriyasathaporn). All authors have read and agreed to the published version of the manuscript.

Funding

This research project is supported by the National Research Council of Thailand (NRCT): NRCT5-RGJ63004-080.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Animal Care and Use Committee, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai, Thailand (reference number S27/2563, date of approval: 18 September 2020).

Informed Consent Statement

Informed consent was obtained from the owners.

Data Availability Statement

The data presented in this study are available in article.

Acknowledgments

The authors would like to thank Khajornsak Tragoolpua and Sirikwan Sangboonruang from the Division of Clinical Microbiology, Rujirek Chaiwongsa, and Yupanun Wuttiin from the Division of Transfusion Science, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand, for their advice on laboratory methods and for allowing the use of laboratory equipment.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Mickelson, M.A.; Mans, C.; Colopy, S.A. Principles of Wound Management and Wound Healing in Exotic Pets. Vet. Clin. N. Am. Exot. Anim. Pract. 2016, 19, 33–53. [Google Scholar] [CrossRef] [PubMed]
  2. Pomba, C.; Rantala, M.; Greko, C.; Baptiste, K.E.; Catry, B.; van Duijkeren, E.; Mateus, A.; Moreno, M.A.; Pyörälä, S.; Ružauskas, M.; et al. Public health risk of antimicrobial resistance transfer from companion animals. J. Antimicrob. Chemother. 2017, 72, 957–968. [Google Scholar] [CrossRef] [PubMed]
  3. Beco, L.; Guaguère, E.; Lorente Méndez, C.; Noli, C.; Nuttall, T.; Vroom, M. Suggested guidelines for using systemic antimicrobials in bacterial skin infections: Part 2—Antimicrobial choice, treatment regimens and compliance. Vet. Rec. 2013, 172, 156–160. [Google Scholar] [CrossRef] [PubMed]
  4. Suriyasathaporn, W.; Chupia, V.; Sing-Lah, T.; Wongsawan, K.; Mektrirat, R.; Chaisri, W. Increases of antibiotic resistance in excessive use of antibiotics in smallholder dairy farms in northern Thailand. Asian-Australas J. Anim. Sci. 2012, 25, 1322–1328. [Google Scholar] [CrossRef] [PubMed]
  5. Singh, S.; Young, A.; McNaught, C.-E. The physiology of wound healing. Surgery 2017, 35, 473–477. [Google Scholar] [CrossRef]
  6. Yeaman, M.R. Platelets: At the nexus of antimicrobial defence. Nat. Rev. Microbiol. 2014, 12, 426–437. [Google Scholar] [CrossRef]
  7. Soares, C.S.; Babo, P.S.; Reis, R.L.; Carvalho, P.P.; Gomes, M.E. Platelet-Derived Products in Veterinary Medicine: A New Trend or an Effective Therapy? Trends Biotechnol. 2021, 39, 225–243. [Google Scholar] [CrossRef]
  8. Etulain, J. Platelets in wound healing and regenerative medicine. Platelets 2018, 29, 556–568. [Google Scholar] [CrossRef]
  9. Kobayashi, E.; Flückiger, L.; Fujioka-Kobayashi, M.; Sawada, K.; Sculean, A.; Schaller, B.; Miron, R.J. Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin. Oral Investig. 2016, 20, 2353–2360. [Google Scholar] [CrossRef]
  10. Oneto, P.; Zubiry, P.R.; Schattner, M.; Etulain, J. Anticoagulants Interfere with the Angiogenic and Regenerative Responses Mediated by Platelets. Front. Bioeng. Biotechnol. 2020, 8, 223. [Google Scholar] [CrossRef]
  11. Dohan Ehrenfest, D.M.; Rasmusson, L.; Albrektsson, T. Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009, 27, 158–167. [Google Scholar] [CrossRef] [PubMed]
  12. Castro, A.B.; Herrero, E.R.; Slomka, V.; Pinto, N.; Teughels, W.; Quirynen, M. Antimicrobial capacity of Leucocyte- and Platelet Rich Fibrin against periodontal pathogens. Sci. Rep. 2019, 9, 8188. [Google Scholar] [CrossRef] [PubMed]
  13. Badade, P.S.; Mahale, S.A.; Panjwani, A.A.; Vaidya, P.D.; Warang, A.D. Antimicrobial effect of platelet-rich plasma and platelet-rich fibrin. Indian J. Dent. Res. 2016, 27, 300–304. [Google Scholar] [CrossRef] [PubMed]
  14. Attili, A.R.; Iacoucci, C.; Serri, E.; Cuteri, V.; Cantalamessa, A.; Linardi, M.; Rifici, C.; Mazzullo, G.; Rossi, G.; Galosi, L.; et al. Antibacterial Properties of Canine Platelet-Rich Plasma and Other Non-Transfusional Hemo-Components: An in vitro Study. Front. Vet. Sci. 2021, 8, 746809. [Google Scholar] [CrossRef] [PubMed]
  15. Yeaman, M.R. Platelets in defense against bacterial pathogens. Cell. Mol. Life Sci. 2010, 67, 525–544. [Google Scholar] [CrossRef] [PubMed]
  16. Yeaman, M.R. The Role of Platelets in Antimicrobial Host Defense. Clin. Infect. Dis. 1997, 25, 951–970. [Google Scholar] [CrossRef]
  17. Zielinski, T.; Wachowicz, B.; Saluk-Juszczak, J.; Kaca, W. The generation of superoxide anion in blood platelets in response to different forms of Proteus mirabilis lipopolysaccharide: Effects of staurosporin, wortmannin, and indomethacin. Thromb. Res. 2001, 103, 149–155. [Google Scholar] [CrossRef]
  18. Aktan, I.; Dunkel, B.; Cunningham, F.M. Equine platelets inhibit E. coli growth and can be activated by bacterial lipopolysaccharide and lipoteichoic acid although superoxide anion production does not occur and platelet activation is not associated with enhanced production by neutrophils. Vet. Immunol. Immunopathol. 2013, 152, 209–217. [Google Scholar] [CrossRef]
  19. Kaper, J.B.; Nataro, J.P.; Mobley, H.L.T. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2004, 2, 123–140. [Google Scholar] [CrossRef]
  20. Mangram, A.J.; Horan, T.C.; Pearson, M.L.; Silver, L.C.; Jarvis, W.R. Guideline for Prevention of Surgical Site Infection, 1999. Infect. Control Hosp. Epidemiol. 1999, 20, 247–280. [Google Scholar] [CrossRef] [PubMed]
  21. Gómez-Beltrán, D.A.; Villar, D.; López-Osorio, S.; Ferguson, D.; Monsalve, L.K.; Chaparro-Gutiérrez, J.J. Prevalence of Antimicrobial Resistance in Bacterial Isolates from Dogs and Cats in a Veterinary Diagnostic Laboratory in Colombia from 2016–2019. Vet. Sci. 2020, 7, 173. [Google Scholar] [CrossRef] [PubMed]
  22. Bertelloni, F.; Cagnoli, G.; Ebani, V.V. Virulence and Antimicrobial Resistance in Canine Staphylococcus spp. Isolates. Microorganisms 2021, 9, 515. [Google Scholar] [CrossRef] [PubMed]
  23. Warin, R.; Vongchan, P.; Suriyasathaporn, W.; Boripun, R.; Suriyasathaporn, W. In Vitro Assessment of Lyophilized Advanced Platelet-Rich Fibrin from Dogs in Promotion of Growth Factor Release and Wound Healing. Vet. Sci. 2022, 9, 566. [Google Scholar] [CrossRef] [PubMed]
  24. CLSI. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals, 4th ed.; CLSI Supplement VET08; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2018. [Google Scholar]
  25. CLSI. Methods for Determining Bactericidal Activity of Antimicrobial Agents. Approved Guideline; CLSI Document M26-A; Clinical and Laboratory Standard Institute: Wayne, PA, USA, 1998. [Google Scholar]
  26. CLSI. Performance Standard for Antimicrobial Susceptibility Testing, 28th ed.; CLSI Supplement M100; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2018. [Google Scholar]
  27. Jyung, S.; Kang, J.W.; Kang, D.H.L. Monocytogens exhibited less cell membrane damage, lipid peroxidation, and intracellular reactive oxygen species accumulation after plasma-activated water treatment compared to E. coli O157:H7 and S. Typhimurium. Food Microbiol. 2022, 108, 104098. [Google Scholar] [CrossRef] [PubMed]
  28. Narayanaswamy, R.; Patro, B.P.; Jeyaraman, N.; Gangadaran, P.; Rajendran, R.L.; Nallakumarasamy, A.; Jeyaraman, M.; Ramani, P.; Ahn, B.C. Evolution and Clinical Advances of Platelet-Rich Fibrin in Musculoskeletal Regeneration. Bioengineering 2023, 10, 58. [Google Scholar] [CrossRef]
  29. Miron, R.J.; Fujioka-Kobayashi, M.; Bishara, M.; Zhang, Y.; Hernandez, M.; Choukroun, J. Platelet-Rich Fibrin and Soft Tissue Wound Healing: A Systematic Review. Tissue Eng. Part B Rev. 2017, 23, 83–99. [Google Scholar] [CrossRef]
  30. Barbon, S.; Stocco, E.; Macchi, V.; Contran, M.; Grandi, F.; Borean, A.; Parnigotto, P.P.; Porzionato, A.; De Caro, R. Platelet-Rich Fibrin Scaffolds for Cartilage and Tendon Regenerative Medicine: From Bench to Bedside. Int. J. Mol. Sci. 2019, 20, 1701. [Google Scholar] [CrossRef]
  31. Barrientos, S.; Stojadinovic, O.; Golinko, M.S.; Brem, H.; Tomic-Canic, M. Growth factors and cytokines in wound healing. Wound Repair. Regen 2008, 16, 585–601. [Google Scholar] [CrossRef]
  32. Alhasyimi, A.A.; Suparwitri, S.; Christnawati, C. Effect of Carbonate Apatite Hydrogel-Advanced Platelet-Rich Fibrin Injection on Osteoblastogenesis during Orthodontic Relapse in Rabbits. Eur. J. Dent. 2021, 15, 412–419. [Google Scholar] [CrossRef]
  33. Alhasyimi, A.A.; Pudyani, P.P.; Asmara, W.; Ana, I.D. Enhancement of post-orthodontic tooth stability by carbonated hydroxyapatite-incorporated advanced platelet-rich fibrin in rabbits. Orthod. Craniofac. Res. 2018, 21, 112–118. [Google Scholar] [CrossRef]
  34. Sindhusha, V.B.; Ramamurthy, J. Comparison of Antimicrobial Activity of Injectable Platelet-Rich Fibrin (i-PRF) and Leukocyte and Platelet-Rich Fibrin (l-PRF) Against Oral Microbes: An In Vitro Study. Cureus 2023, 15, e46196. [Google Scholar] [CrossRef]
  35. Karde, P.A.; Sethi, K.S.; Mahale, S.A.; Khedkar, S.U.; Patil, A.G.; Joshi, C.P. Comparative evaluation of platelet count and antimicrobial efficacy of injectable platelet-rich fibrin with other platelet concentrates: An in vitro study. J. Indian Soc. Periodontol. 2017, 21, 97–101. [Google Scholar] [CrossRef]
  36. Decristophoris, P.; Fasola, A.; Benagli, C.; Tonolla, M.; Petrini, O. Identification of Staphylococcus intermedius Group by MALDI-TOF MS. Syst. Appl. Microbiol. 2011, 34, 45–51. [Google Scholar] [CrossRef]
  37. Bhooshan, S.; Negi, V.; Khatri, P.K. Staphylococcus pseudintermedius: An undocumented, emerging pathogen in humans. GMS Hyg. Infect. Control 2020, 15, 32. [Google Scholar] [CrossRef]
  38. Magiorakos, A.P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18, 268–281. [Google Scholar] [CrossRef] [PubMed]
  39. Van Duijkeren, E.; Catry, B.; Greko, C.; Moreno, M.A.; Pomba, M.C.; Pyörälä, S.; Ružauskas, M.; Sanders, P.; Threlfall, E.J.; Torren-Edo, J.; et al. Review on methicillin-resistant Staphylococcus pseudintermedius. J. Antimicrob. Chemother. 2011, 66, 2705–2714. [Google Scholar] [CrossRef] [PubMed]
  40. Saputra, S.; Jordan, D.; Worthing, K.A.; Norris, J.M.; Wong, H.S.; Abraham, R.; Trott, D.J.; Abraham, S. Antimicrobial resistance in coagulase-positive staphylococci isolated from companion animals in Australia: A one year study. PLoS ONE 2017, 12, e0176379. [Google Scholar] [CrossRef] [PubMed]
  41. Grönthal, T.; Eklund, M.; Thomson, K.; Piiparinen, H.; Sironen, T.; Rantala, M. Antimicrobial resistance in Staphylococcus pseudintermedius and the molecular epidemiology of methicillin-resistant S. pseudintermedius in small animals in Finland. J. Antimicrob. Chemother. 2017, 72, 1021–1030. [Google Scholar] [CrossRef]
  42. Gagetti, P.; Wattam, A.R.; Giacoboni, G.; De Paulis, A.; Bertona, E.; Corso, A.; Rosato, A.E. Identification and molecular epidemiology of methicillin resistant Staphylococcus pseudintermedius strains isolated from canine clinical samples in Argentina. BMC Vet. Res. 2019, 15, 264. [Google Scholar] [CrossRef]
  43. Van Duijkeren, E.; Kamphuis, M.; van der Mije, I.C.; Laarhoven, L.M.; Duim, B.; Wagenaar, J.A.; Houwers, D.J. Transmission of methicillin-resistant Staphylococcus pseudintermedius between infected dogs and cats and contact pets, humans and the environment in households and veterinary clinics. Vet. Microbiol. 2011, 150, 338–343. [Google Scholar] [CrossRef]
  44. Dohan, D.M.; Choukroun, J.; Diss, A.; Dohan, S.L.; Dohan, A.J.; Mouhyi, J.; Gogly, B. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part III: Leucocyte activation: A new feature for platelet concentrates? Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2006, 101, e51–e55. [Google Scholar] [CrossRef] [PubMed]
  45. Dohan, D.M.; Choukroun, J.; Diss, A.; Dohan, S.L.; Dohan, A.J.; Mouhyi, J.; Gogly, B. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part II: Platelet-related biologic features. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2006, 101, e45–e50. [Google Scholar] [CrossRef]
  46. Noaman, K.A.; Alharbi, N.S.; Khaled, J.M.; Kadaikunnan, S.; Alobaidi, A.S.; Almazyed, A.O.; Aldosary, M.S.; Al Rashedi, S. The transmutation of Escherichia coli ATCC 25922 to small colony variants (SCVs) E. coli strain as a result of exposure to gentamicin. J. Infect. Public Health 2023, 16, 1821–1829. [Google Scholar] [CrossRef] [PubMed]
  47. Burnouf, T.; Chou, M.L.; Wu, Y.W.; Su, C.Y.; Lee, L.W. Antimicrobial activity of platelet (PLT)-poor plasma, PLT-rich plasma, PLT gel, and solvent/detergent-treated PLT lysate biomaterials against wound bacteria. Transfusion 2013, 53, 138–146. [Google Scholar] [CrossRef]
  48. Bayer, A.S.; Cheng, D.; Yeaman, M.R.; Corey, G.R.; McClelland, R.S.; Harrel, L.J.; Fowler, V.G., Jr. In vitro resistance to thrombin-induced platelet microbicidal protein among clinical bacteremic isolates of Staphylococcus aureus correlates with an endovascular infectious source. Antimicrob. Agents Chemother. 1998, 42, 3169–3172. [Google Scholar] [CrossRef] [PubMed]
  49. Wu, B.Q.; Zhi, M.J.; Liu, H.; Huang, J.; Zhou, Y.Q.; Zhang, T.T. Inhibitory effects of lipoteichoic acid from Staphylococcus aureus on platelet function and platelet-monocyte aggregation. Inflamm. Res. 2011, 60, 775–782. [Google Scholar] [CrossRef]
  50. Anitua, E.; Alonso, R.; Girbau, C.; Aguirre, J.J.; Muruzabal, F.; Orive, G. Antibacterial effect of plasma rich in growth factors (PRGF®-Endoret®) against Staphylococcus aureus and Staphylococcus epidermidis strains. Clin. Exp. Dermatol. 2012, 37, 652–657. [Google Scholar] [CrossRef]
  51. Rodriguez, P.G.; Felix, F.N.; Woodley, D.T.; Shim, E.K. The role of oxygen in wound healing: A review of the literature. Dermatol. Surg. 2008, 34, 1159–1169. [Google Scholar] [CrossRef]
  52. Zander, D.M.; Klinger, M. The blood platelets contribution to innate host defense—What they have learned from their big brothers. Biotechnol. J. 2009, 4, 914–926. [Google Scholar] [CrossRef]
  53. Krötz, F.; Sohn, H.Y.; Gloe, T.; Zahler, S.; Riexinger, T.; Schiele, T.M.; Becker, B.F.; Theisen, K.; Klauss, V.; Pohl, U. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 2002, 100, 917–924. [Google Scholar] [CrossRef]
  54. Rodríguez Sánchez, F.; Verspecht, T.; Castro, A.B.; Pauwels, M.; Andrés, C.R.; Quirynen, M.; Teughels, W. Antimicrobial Mechanisms of Leucocyte- and Platelet Rich Fibrin Exudate Against Planktonic Porphyromonas gingivalis and Within Multi-Species Biofilm: A Pilot Study. Front. Cell Infect. Microbiol. 2021, 11, 722499. [Google Scholar] [CrossRef] [PubMed]
  55. Kohanski, M.A.; Dwyer, D.J.; Hayete, B.; Lawrence, C.A.; Collins, J.J. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007, 130, 797–810. [Google Scholar] [CrossRef] [PubMed]
  56. Masselli, E.; Pozzi, G.; Vaccarezza, M.; Mirandola, P.; Galli, D.; Vitale, M.; Carubbi, C.; Gobbi, G. ROS in Platelet Biology: Functional Aspects and Methodological Insights. Int. J. Mol. Sci. 2020, 21, 4866. [Google Scholar] [CrossRef] [PubMed]
  57. Wachowicz, B.; Olas, B.; Zbikowska, H.M.; Buczyński, A. Generation of reactive oxygen species in blood platelets. Platelets 2002, 13, 175–182. [Google Scholar] [CrossRef]
Animals 13 03786 g001
Figure 1. Schematic outline of experiments determining antimicrobial effects and antimicrobial mechanism of canine platelet-rich fibrin (cPRF) using time–kill assay and fluorescent probe 2,7-dichlorodihydrofluorescein diacetate (H2DCFDA). HRP: horseradish peroxidase. PBS: phosphate buffer saline.
Figure 1. Schematic outline of experiments determining antimicrobial effects and antimicrobial mechanism of canine platelet-rich fibrin (cPRF) using time–kill assay and fluorescent probe 2,7-dichlorodihydrofluorescein diacetate (H2DCFDA). HRP: horseradish peroxidase. PBS: phosphate buffer saline.
Animals 13 03786 g001
Animals 13 03786 g002
Figure 2. The time–kill assay images were captured for (A) E. coli ATCC 25922 or ECs; (B) E. coli clinical isolate or ECc; (C) Methicillin-resistant S. pseudintermedius clinical isolate or MR-SPc; and (D) S. aureus ATCC 29213 or SAs for each group, including growth control, cPRF, and drug control. The lower series figure indicates the antimicrobial properties of cPRF, growth control, and drug control against (E) ECs; (F) ECc; (G) MR-SPc; and (H) SAs at 0.5, 4, 8, and 24 h. Based on the results of a generalized linear mixed model, the x, y, and z letters indicate differences between groups within the same time at p < 0.05, and * indicates differences in the specified time from 0.5 h within cPRF at p < 0.05.
Figure 2. The time–kill assay images were captured for (A) E. coli ATCC 25922 or ECs; (B) E. coli clinical isolate or ECc; (C) Methicillin-resistant S. pseudintermedius clinical isolate or MR-SPc; and (D) S. aureus ATCC 29213 or SAs for each group, including growth control, cPRF, and drug control. The lower series figure indicates the antimicrobial properties of cPRF, growth control, and drug control against (E) ECs; (F) ECc; (G) MR-SPc; and (H) SAs at 0.5, 4, 8, and 24 h. Based on the results of a generalized linear mixed model, the x, y, and z letters indicate differences between groups within the same time at p < 0.05, and * indicates differences in the specified time from 0.5 h within cPRF at p < 0.05.
Animals 13 03786 g002
Animals 13 03786 g003
Figure 3. Numbers of colonies of E. coli ATCC 25922 culturing under the control condition, PRF-SR as enzymatic treatment of PRF, and cPRF at 0.5, 4, 8, and 24 h (h). Based on the results of a generalized linear mixed model, x and y are different letters indicating the differences between groups within the same time at p < 0.05, and * indicates differences of the specified time from 0.5 h within cPRF at p < 0.05.
Figure 3. Numbers of colonies of E. coli ATCC 25922 culturing under the control condition, PRF-SR as enzymatic treatment of PRF, and cPRF at 0.5, 4, 8, and 24 h (h). Based on the results of a generalized linear mixed model, x and y are different letters indicating the differences between groups within the same time at p < 0.05, and * indicates differences of the specified time from 0.5 h within cPRF at p < 0.05.
Animals 13 03786 g003
Animals 13 03786 g004
Figure 4. ROS generation in E. coli ATCC 25922 culturing under control conditions, cPRF with suppressed ROS (PRF-SR), and cPRF at 0.5, 4, 8, and 24 h (h). Based on the results of a generalized linear mixed model, x and y are different letters indicating differences between groups within the same time at p < 0.05.
Figure 4. ROS generation in E. coli ATCC 25922 culturing under control conditions, cPRF with suppressed ROS (PRF-SR), and cPRF at 0.5, 4, 8, and 24 h (h). Based on the results of a generalized linear mixed model, x and y are different letters indicating differences between groups within the same time at p < 0.05.
Animals 13 03786 g004
Table 1. Minimal inhibitory concentration (MIC) and their interpretations as susceptible (S), intermediate (I), and resistant (R) for E. coli clinical isolate (ECc), S. pseudintermedius clinical isolate (SPc), E. coli ATCC 25922 (ECs), and S. aureus ATCC 29213 (SAs) determined using automated identification systems (VITEK® 2 COMPACT, bioMerieux, Marcy l’Etoile, France).
Table 1. Minimal inhibitory concentration (MIC) and their interpretations as susceptible (S), intermediate (I), and resistant (R) for E. coli clinical isolate (ECc), S. pseudintermedius clinical isolate (SPc), E. coli ATCC 25922 (ECs), and S. aureus ATCC 29213 (SAs) determined using automated identification systems (VITEK® 2 COMPACT, bioMerieux, Marcy l’Etoile, France).
Antibiotics Tested for All Isolates
IsolatesAKCDOENRCNMARF
ECc 1≤2S≤2S8I0.5S≤1S≤0.5S≤16S
ECc 2≤2S4S1S0.5S≤1S1S≤16S
ECs≤4S≤8S≤2S--≤1S--≤16S
SPc 1≤2S≥64R8I≥4R≥16R≥4R≤16S
SPc 2≤2S8S≥16R≥4R8I≥4R≤16S
SAs≤2S≤8S0.5S--≤1S--≤32S
Antibiotics tested for Gram-negative bacteria
AMCAMPEFTCLKFIPMN
ECc 14S≥32R≤1S8S4S≤0.25S≤2S
ECc 24S8S≤1S8S16I≤0.25S≤2S
ECs2/1S8S----4S≤0.25S--
Antibiotics tested for Gram-positive bacteria
PCVNDAFFCMHOXPRASXT
SPc 1≥0.5R≥8R≥4R≤4S8I≥4R2R≥3R
SPc 2≥0.5R4I≥4R≤4S1S≥4R1I≥3R
SAs≥0.5R--0.25S--0.5S≤0.5S--≤0.5S
Amikacin (AK), Amoxicillin/clavulanic acid (AMC), Ampicillin (AMP), Benzylpenicillin (P), Ceftiofur (EFT), Cefalexin (CL), cefovecin (CVN), Cephalotin (KF), Chloramphenicol (C), Clindamycin (DA), Doxycycline (DO), Enrofloxacin (ENR), Florfenicol (FFC), Gentamicin (CN), Imipenem (IPM), Marbofloxacin (MAR), Minocycline (MH), Nitrofurantoin (F), Neomycin (N), Oxacillin (OX), Pradofloxacin (PRA), Trimetroprim/sulfamethoxacin (SXT).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Warin, R.; Vongchan, P.; Suriyasathaporn, W.; Hall, D.C.; Boripun, R.; Suriyasathaporn, W. In Vitro Antimicrobial Properties and Their Mechanisms in Relation to Reactive Oxygen Species of Canine Platelet-Rich Fibrin. Animals 2023, 13, 3786. https://doi.org/10.3390/ani13243786

AMA Style

Warin R, Vongchan P, Suriyasathaporn W, Hall DC, Boripun R, Suriyasathaporn W. In Vitro Antimicrobial Properties and Their Mechanisms in Relation to Reactive Oxygen Species of Canine Platelet-Rich Fibrin. Animals. 2023; 13(24):3786. https://doi.org/10.3390/ani13243786

Chicago/Turabian Style

Warin, Ravisa, Preeyanat Vongchan, Witaya Suriyasathaporn, David C. Hall, Ratchadaporn Boripun, and Wanna Suriyasathaporn. 2023. "In Vitro Antimicrobial Properties and Their Mechanisms in Relation to Reactive Oxygen Species of Canine Platelet-Rich Fibrin" Animals 13, no. 24: 3786. https://doi.org/10.3390/ani13243786

APA Style

Warin, R., Vongchan, P., Suriyasathaporn, W., Hall, D. C., Boripun, R., & Suriyasathaporn, W. (2023). In Vitro Antimicrobial Properties and Their Mechanisms in Relation to Reactive Oxygen Species of Canine Platelet-Rich Fibrin. Animals, 13(24), 3786. https://doi.org/10.3390/ani13243786

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop